IBDV VP3 Specific Neutra™ Antibody Products

Are you struggling to overcome challenges in IBDV research, such as inefficient viral neutralization, inconsistent assay results, or limited tools for studying VP3’s role in pathogenesis? Creative Biolabs’ IBDV VP3 specific Neutra™ antibody products leverage advanced monoclonal antibody technology and structure-guided design to deliver high-affinity, validated tools that streamline viral neutralization studies and accelerate poultry vaccine development.

Introduction to IBDV VP3

Infectious bursal disease virus VP3 minor capsid protein (IBDV VP3) is a multifunctional component critical for viral replication and pathogenesis. As a structural protein, it forms part of the viral capsid and interacts with the viral polymerase VP1, facilitating genome packaging and virion assembly. Expressed during the late stages of infection, VP3 is indispensable for maintaining viral infectivity and evading host immune responses.

• Structure

IBDV VP3 adopts a modular architecture, featuring a conserved N-terminal domain that mediates dimerization and a C-terminal region essential for RNA binding. Structural studies reveal its role in forming a scaffold for the viral capsid, where it coordinates with VP2 to stabilize the icosahedral lattice. This unique arrangement enables VP3 to act as a hub for recruiting viral components during assembly. Cryo-EM analyses further highlight VP3’s dynamic conformational changes during capsid maturation, underscoring its functional versatility.

• Related Signaling Pathways

VP3 interferes with host antiviral pathways by suppressing interferon (IFN) production via sequestration of viral double-stranded RNA, thereby inhibiting activation of the RIG-I-like receptor (RLR) pathway. It also modulates the NF-κB signaling cascade, reducing pro-inflammatory cytokine expression and enabling viral immune evasion. These interactions make VP3 a focal point for understanding IBDV-host interplay.

Fig.1 Apoptosis and immunosuppression role of IBDV VP3.¹

• Pathologies

IBDV causes infectious bursal disease, a highly contagious viral infection targeting the bursa of Fabricius in young chickens. The disease leads to immunosuppression, rendering poultry susceptible to secondary infections and contributing to substantial economic losses in the global poultry industry.

Applications of Anti-IBDV VP3 Neutralizing Antibodies

• Diagnostic Development for Early Infection Detection

Anti-VP3 antibodies enable rapid, high-sensitivity detection of IBDV in clinical samples. ELISA-based assays utilizing these antibodies are critical for monitoring outbreaks and implementing timely biosecurity measures in poultry farms.

• Structural Virology and Drug Discovery

Neutralizing antibodies serve as molecular tools for resolving VP3’s structural dynamics during capsid assembly. These insights guide the design of small-molecule inhibitors targeting VP3’s RNA-binding domain, offering a pathway to antiviral drug development.

• Vaccine Efficacy Assessment

VP3-specific neutralizing antibodies are indispensable for quantifying immune responses in vaccinated flocks. Neutralization assays using these antibodies provide robust correlates of protection, accelerating the validation of next-generation IBDV vaccines.

• Therapeutic Candidate Screening

High-affinity anti-VP3 antibodies inhibit viral replication in vitro, making them valuable for screening therapeutic candidates. These antibodies also serve as benchmarks for engineering biologics that disrupt VP3-mediated immune evasion.

Our Anti-IBDV VP3 Antibodies

Anti-IBDV VP3 neutralizing antibodies are pivotal for dissecting viral replication mechanisms and developing targeted interventions. Creative Biolabs' antibodies exhibit exceptional specificity for conformational epitopes critical for VP3’s RNA-binding and capsid assembly functions. Validated in neutralization assays, these antibodies block viral entry, inhibit capsid formation, and reduce infectivity in cell cultures. Applications include:

- Quantifying VP3 expression via ELISA, WB, IHC.

- Mapping VP3-protein interactions to identify novel therapeutic targets.

- Evaluating vaccine candidates by measuring VP3-specific neutralizing antibody titers in immunized animals.

Creative Biolabs' IBDV VP3 specific Neutra™ antibody products provide researchers and vaccine developers with precision tools to overcome key challenges in IBDV research. Engineered for high specificity and neutralizing activity, our antibodies are validated across applications, from diagnostics to therapeutic development.

Contact our scientific team today to discuss your project requirements and request customized solutions.

REFERENCE

1. Qin, Yao, and Shijun J. Zheng. "Infectious bursal disease virus-host interactions: multifunctional viral proteins that perform multiple and differing jobs." International journal of molecular sciences 18.1 (2017): 161. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms18010161